S.F. BIOTECH INKS $700M ALLIANCE

Sirna Therapeutics, which is pioneering a new class of therapeutics that turn off specific genes that underlie diseases, entered into an alliance worth as much as $700 million with GlaxoSmithKline to develop treatments for respiratory diseases. San Francisco Business Times (http://charlotte.bizjournals.com/sanfrancisco/stories/2006/04/10/story5.html)